Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer  by Barlési, Fabrice et al.
Prognostic value of combination of Cyfra 21-1, CEA
and NSE in patients with advanced non-small cell
lung cancer
Fabrice Barl !esia,*, C !eline Gimeneza, Jean-Philippe Torreb,
Christophe Doddolic, Julien Mancinid, Laurent Greilliera, Fran-cois Roux
e,
Jean-Pierre Kleisbauera
aFaculty of Medicine, Universit !e de la m!editerran!ee (Aix-Marseille II), Assistance Publique H #opitaux de
Marseille, Service d’Oncologie Thoracique, H #opital Sainte-Marguerite, 270, Bd de Sainte-Marguerite,
13274 Marseille, Cedex 09, France
bD !epartement d’Information M!edicale, Assistance Publique, H #opitaux de Marseille, H #opital de la Timone,
264, Bd Saint Pierre, 13385 Marseille, Cedex 05, France
cFaculty of Medicine, Universit !e de la m!editerran!ee (Aix-Marseille II), Assistance Publique H #opitaux de
Marseille, Service de Chirurgie Thoracique, H #opital Sainte-Marguerite, 270, Bd de Sainte-Marguerite,
13274 Marseille, Cedex 09, France
dFaculty of Medicine, D !epartement d’Information M !edicale, Universit !e de la m!editerran!ee (Aix-Marseille
II), Assistance Publique H #opitaux de Marseille, H #opital Sainte-Marguerite, 270, Bd de Sainte-Marguerite,
13274 Marseille, Cedex 09, France
eLaboratoire de M!edecine Nucl !eaire, Faculty of Medicine, Universit !e de la m!editerran !ee (Aix-Marseille II),
Assistance Publique H #opitaux de Marseille, H #opital de la Timone, 264, Bd Saint Pierre, 13385 Marseille,
Cedex 05, France
Received 20 February 2003; accepted 6 November 2003
Summary Objective: To assess the value of Cyfra 21-1, carcino-embryonic antigen
(CEA) and neuron-specific enolase (NSE) combined, all three together as prognostic
factors in advanced stage non-small cell lung cancer (NSCLC) patients.
Patients and methods: Serum samples from untreated NSCLC patients were
prospectively collected. All assays were performed using commercial kits blind to
clinical information. Serum levels of CEA, NSE and Cyfra 21-1 higher than 10, 13 and
3.5 ng/ml, respectively, were considered as elevated.
Results: 264 patients (men, 87%), with Performans Status (PS) of 0/1 in 80% and
stage IV disease in 65% were studied. Cyfra 21-1, CEA and NSE were elevated in
52.5%, 41.8% and 33.2% of patients, respectively. Median survival was 9 months
(range, 1–77). Cyfra 21-1, age, PS, stage as well as the combination of the three
markers together correlated with prognosis in univariate analysis. Multivariate
analysis demonstrated that age X65 years (HR¼ 1.3 [1.02–1.70], p¼ 0.03), PS 2
(HR¼ 4.3 [3.13–6.11], po0.0001), Cyfra 21-1X3.5 ng/ml (HR¼ 1.3 [1.06–1.78],
p¼ 0.01) and the combination of the three markers (HR¼ 1.06 [1.009–1.13],
p¼ 0.02) remained prognostic determinants.
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Conclusion: Combining Cyfra 21-1, NSE and CEA correlated with prognosis in a
significant and independent manner.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Lung cancer is the major cause of cancer-related
death in western countries. Research on prognostic
factors in non-small cell lung cancer (NSCLC) is of
great importance because it potentially leads to a
better and perhaps tailored management of patients.
Some serum markers are potential prognostic factors
in NSCLC patients. However, serum markers are
interesting if they give a supplementary and inde-
pendent information on prognosis which is currently
principally based on Performans Status (PS) and TNM
classification.1 Increased level of a recognized and
independent marker should be able to modify the
therapeutic strategy as for nodal or metastatic status
for example. None of the markers is actually
considered when deciding treatment option.
Among these NSCLC markers Cyfra 21-1, a
fragment of cytokeratin subunit 19, is of great
interest. Indeed, Cyfra 21-1 was found in several
studies to be correlated with TNM stage and PS and
reflecting prognosis of NSCLC patients in an
independent manner.2–7 Then, Pujol and others
suggested that Cyfra 21-1 should be regarded as a
co-variable in future NSCLC trials.2
Neuron-specific enolase (NSE) was evaluated in
NSCLC and high NSE level was found to be of poor
prognosis.8 High NSE level could reflect a neuro-
endocrine component in NSCLC leading to better
response to chemotherapy9 but poorest outcome.
However, prognostic implication of NSE in NSCLC
patients management has to be clearly specified.
Carcino-embryonic antigen (CEA) is currently not
considered in prognostic evaluation of NSCLC patients
given the results of previous studies.10,11 Never-
theless, discordance persists between authors, and
CEA could be useful under particular conditions such
as response evaluation or resected patients.12,13
In this study, we hypothesize that combination of
Cyfra 21-1, CEA and NSE considered together could
have a better prognostic value in NSCLC than each
of them considered separately.
Patients and methods
Patients
Serum samples from untreated lung cancer patients
were prospectively collected from January 1994 to
December 2000. Eligibility criteria consisted of
histologically or cytologically proven NSCLC. Pa-
tients suffering from small cell lung cancer were
not eligible. Histological subclassification was done
according to the World Health Organization classi-
fication.14 PS was estimated using the Eastern
Cooperative Oncology Group scale. Clinical exam-
ination, chest, abdomen and brain computed
tomographic scan, bronchoscopy and bone scanning
were carried out systematically. Staging was done
upon these procedures according to the TNM
classification.15
Treatments
A medical panel composed of thoracic surgeons,
chest physicians and radiotherapists examined each
patient’s record. Treatments were decided accord-
ing to the standard of care. Stage IIIB patients were
generally treated using an association of sequential
chemotherapy (cisplatin and etoposide) and thor-
acic radiotherapy (60 grays in 30 fractions), while
stage IV patients received platinum-based che-
motherapy (with vinorelbine, gemcitabine or pa-
clitaxel) for a maximum of six cycles.
Biochemical measurements
Serum samples were obtained from each patient
before initiation of treatment. Fresh serum was
collected and cooled after sampling, than stored at
201C until dosage. All assays were performed
using commercial kits (ELSA 2 CEA CisBiointerna-
tionalt; ELSA Cyfra 21-1 CisBiointernationalt; NSE-
Ria Pharmaciat) blind to clinical information.
Serum levels of CEA, NSE and Cyfra 21-1 were
considered as elevated when they were superior or
equal to 10, 13 and 3.5 ng/ml, respectively. Cut-off
value of 10 ng/ml for CEA was determined accord-
ing to our previous findings.12 Cut-off values of
3.5 ng/ml for Cyfra 21-1 and 13 ng/ml for NSE were
based on previously published results.2,8,9
Statistics
Survival data were updated in July 2003. One
patient was lost. Probability of survival was
estimated using the Kaplan–Meier method. Differ-
ences between survival were tested by means of
log-rank test. A multivariate regression analysis
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was done with Cox’s regression using the forward
maximum likelihood method. All variables with a p-
value less than 0.20 at the time of univariate
analysis were entered into the model. A p-value
less than 0.05 was considered as significant.
Results
Patients characteristics
Overall, 264 patients with a median age of 62 years
(range, 27–85 years) were studied. Demographic
data and clinical characteristics of patients are
summarized in Table 1. One hundred and eleven
patients (41.8%) had serum level of CEA410 ng/ml,
87 (33.2%) had NSE level413 ng/ml and 138 (52.5%)
had Cyfra 21-1 level43.5 ng/ml. Table 2 summarize
the results for the various combinations of all the
three serum markers measurements.
Survival analysis
Survival was analyzed in the whole patient popula-
tion. Median follow-up was 9 months [range, 1–77
months]. There were 261 events and median
survival was 9 months [range, 1–77]. A significant
difference (p¼ 0.0001) was seen between the
seven categories. In univariate analysis, age (o65
versus X65 years, p¼ 0.01), PS (0/1 versus 2,
po0.00001) and TNM (stage IIIB versus IV,
p¼ 0.01) showed statistically significant influence
on prognosis. Serum level of Cyfra 21-1 (o3.5
versusX3.5 ng/ml, p¼ 0.0001) considered alone or
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Table 1 Patient’s characteristics.
Patients %
Gender Men/Women 230/34 87/13
Age (years) p65/465 163/101 62/38
Histology ADK 90 34
SCC 118 45
LCC 56 21
PS 0/1 129/83 49/31
2 52 20
Stage IIIB 92 35
IV 172 65
ADK, adenocarcinoma; SCC, squamous cell carcinoma;
LCC, large cell carcinoma; and PS, performans status.
Table 2 Results for the various combinations of all









F F F 49 18.5
43.2 F F 62 23.5
43.2 410 F 26 9.8
43.2 F 413 15 6
F 410 F 40 15
F 410 413 10 3.8
F F 413 27 10.2
43.2 410 413 35 13.2
ADK, adenocarcinoma; SCC, squamous cell carcinoma;
and LCC, large cell carcinoma.
Table 3 Results of univariate analysis.
Variable Survival months (median) p (log-rank)
Gender Men/Women 7/9 0.811
Age (years) p65/465 9/8 0.011
PS 0/1 10 o 105
2 2
Stage IIIB 11 0.01
IV 7




Cyfra 21-143.5 7 0.0001
Cyfra 21-1o3.5 12
ADK, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell carcinoma; PS, performans status; CEA, carcino-
embryonic antigen; and NSE, neuron-specific enolase
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combined with CEA and NSE (p¼ 0.0001) also
showed statistically significant influence on prog-
nosis. Overall results of univariate survival analysis
are summarized in Tables 3 and 4. Multivariate
analysis using Cox’s model for the 264 patients
demonstrated that poor PS (i.e. 0/1 versus 2,
po0.0001), age older than 65 years (p¼ 0.03),
level of Cyfra 21-1 higher than 3.5 ng/ml (p¼ 0.01)
and the combination of the three serum tumor
markers considered together (p¼ 0.02) remained
prognostic determinants (Table 5).
Discussion
Several serum markers were tested in NSCLC
patients and proved to be of low value. Indeed,
only Cyfra 21-1 clearly independently predicts
survival. In this study, we hypothesize that combi-
nation of Cyfra 21-1, CEA and NSE considered
together could have a better prognostic value than
each of them considered separately. We showed
differences in survival between patients with
normal and high level of Cyfra 21-1 (p¼ 0.0001)
but not CEA or NSE considered alone. Considered all
three together, Cyfra 21-1, CEA and NSE highly
correlated with survival in univariate analysis
(p¼ 0.0001). Furthermore, Cyfra 21-1 reached
statistical significance in multivariate analysis
(p¼ 0.01) as well as the combination of the three
tumor markers considered together (p¼ 0.02).
Considering the three markers together, adding
NSE and CEA to Cyfra 21-1 demonstrated an
independent value in prognostic evaluation.
A significant additive value of CEA and Cyfra 21-1
in lung adenocarcinoma was showed by Ando and
colleagues.17 Indeed, high levels of both these
markers were correlated with advanced stage of
disease. However, prognostic significance of CEA is
discussed for a long time with conflicting results.
Indeed, some studies showed a negative prognostic
value for CEA7,18 while others did not.19–21 These
discrepancies probably highlight the need for
specific evaluation of CEA in distinct subgroups
according to histology22 or stage of disease.17
Prognostic value of high NSE level did not reach
statistical significance neither in univariate
(p¼ 0.08) nor in multivariate analysis. This was in
discrepancy with previous studies.3,8,9 Indeed, we
applied a cut-off value of 13 ng/ml in accordance
with previously published study.3,8,9 However, a
better specificity for NSCLC could be obtained with
a cut-off value of 20 ng/ml16 but decreasing
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Table 4 Univariate analysis, results for the various combinations of all the three serum markers measurements.
Marker Survival
Cyfra 21-1 (ng/ml) CEA (ng/ml) NSE (ng/ml) Median (months)
F F F 11
43.2 F F 10
43.2 410 F 5
43.2 F 413 4 p¼ 0.0001
F 410 F 13
F 410 413 15
F F 413 10
43.2 410 413 3
CEA, carcino-embryonic antigen; and NSE, neuron-specific enolase.
Table 5 Results of multivariate analysis.
Variable HR p value 95% CI
Age p65/465 years 1.3 0.03 1.02–1.70
PS 0-1/2 4.3 o0.0001 3.13–6.11
TNM IIIB/IV F Ns F
Cyfra 21-1 o3.5/X3.5 1.3 0.016 1.06–1.78
CEA o10/X10 F Ns F
NSE o13/X13 F Ns F
Combination of the three markers 1.06 0.02 1.009–1.13
PS, performans status; CEA, carcino-embryonic antigen; and NSE, neuron-specific enolase.
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sensibility (i.e. the number of patients with high
NSE level). Then, the choice of the most suitable
cut-off value for NSE in the setting of NSCLC has to
be discussed. Prognostic value of Cyfra 21-1 was
confirmed with a significant relation with survival in
multivariate analysis as reported before.2–6 More-
over, we confirmed the optimal cut-off of 3.5 ng/ml
value for Cyfra 21-1 in prognostic evaluation.2,3
Grouped analysis of different markers, each
associated with a possible prognostic value, should
be again investigated because potentially improv-
ing prognostic information23 and use of mathema-
tical tools in this setting could be helpful and more
powerful.24 Regarding our results, more studies of
several blood molecules as prognostic markers are
needed including previously proposed biological
markers such as lactate dehydrogenase, alkaline
phosphatase, albumin, serum sodium, hemoglobin
and leukocytes in the aim to select the most
suitable co-variables for clinical trials.25 Never-
theless, despite their independent prognostic va-
lue, neither Cyfra 21-1 nor the combination of
Cyfra 21-1 with CEA and NSE actually influence the
therapeutic strategy. However, their impact on the
assessment of the efficacy of the chemotherapy
was demonstrated.26,27 Indeed, the decrease of
Cyfra 21-1 level after one cycle of chemotherapy
could predict the clinical and radiological response.
In this way, initial serum markers level is signifi-
cantly correlated with survival and its evolution
could lead to the chemotherapy regimen adapta-
tion. Then, more studies in this setting are needed.
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